2017
DOI: 10.1016/j.cardfail.2017.10.006
|View full text |Cite
|
Sign up to set email alerts
|

Randomized Evaluation of Heart Failure with Preserved Ejection Fraction Patients with Acute Heart Failure and Dopamine (Ropa-Dop) Trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
18
0
1

Year Published

2018
2018
2022
2022

Publication Types

Select...
7
1

Relationship

2
6

Authors

Journals

citations
Cited by 15 publications
(19 citation statements)
references
References 0 publications
0
18
0
1
Order By: Relevance
“…3 In our practice, HF patients have been placed in our observation units under aggressive diuresis protocols with most patients being discharged within 24 h. However, a significant number of HFpEF patients with chronic renal insufficiency will need extended inpatient treatment due to their WRF after diuresis. 4 Such findings support more cautious discharges of HFpEF patients with WRF.…”
mentioning
confidence: 76%
“…3 In our practice, HF patients have been placed in our observation units under aggressive diuresis protocols with most patients being discharged within 24 h. However, a significant number of HFpEF patients with chronic renal insufficiency will need extended inpatient treatment due to their WRF after diuresis. 4 Such findings support more cautious discharges of HFpEF patients with WRF.…”
mentioning
confidence: 76%
“…Greater than 90% of the patients had hypertension. These conditions are associated with increased arterial and left ventricular wall stiffness and reduced venous capacitance that is thought to lead to interstitial fluid expansion and a greater dependence on preload to maintain cardiac output [10, 11]. Maldistribution of fluid therefore results in a reduced GFR in HFpEF, while in HFrEF, WRF is more likely related to left ventricular systolic dysfunction [12].…”
Section: Discussionmentioning
confidence: 99%
“…(в среднем 27 мг) АМКР спиронолактона пациентам с тяжелой ХСН OOO-OV ФК в дополнение к оптимальной терапии, включавшей иАПФ и у 10 % пациентов БАБ, позволяло достоверно снижать риск смерти на 27 %, причем как внезапной, так и связанной с обострением декомпенсации [422] [440,449] . Однако контролируемые клинические исследования либо не выявили преимуществ длительного применения фуросемида [450], либо показали увеличичение риска развития нарушения функции почек [451] .…”
Section: антагонисты минералокортикоидных рецепторов (амкр)unclassified